BioGaia confirms extended agreement with Nestlé for clinical research and NPD

By Nathan Gray

- Last updated on GMT

Related tags New product development Clinical trial

Nestlé extend BioGaia deal to include research and product development
Swedish probiotic player BioGaia has broadened and strengthened its ties with food manufacturing giant Nestlé by agreeing a deal for clinical research and new product development (NPD), according to the firm.

The move comes approximately two years after BioGaia sold the rights for the use of Lactobacillus reuteri​ Protectis in infant formula to Nestle for the remainder of the patent lifetime.

However, the two companies have now entered in to a new 'supplementary agreement' which will involve the provision and development of pre-clinical and clinical studies in addition to new product development for Nestlé.

“We are of course very satisfied with this agreement, which gives us additional financial resources, improved profits and a great opportunity for us to develop a number of interesting products for Nestlé,"​ said BioGaia president Peter Rothschild.

If the development is successful, these products will be produced by BioGaia and sold to Nestlé, BioGaia added.

Existing deal

As part of the original deal, signed in February 2012, BioGaia received €40 million up-front and a commitment to a further €10.8 million during the period 2014 to 2017 - upon achievement of certain milestones.

BioGaia confirmed that the first milestone payment of €3.6 million was received in February this year.

The new agreement will provide BioGaia with further royalties of around SEK 92 million (approximately €10.4 million) over a three-year period, starting during the second quarter of 2014. As part of the deal BioGaia will carry out specific clinical studies in the paediatric area, the firm said.

Furthermore, the agreement means that BioGaia will immediately receive the remaining milestone payments totalling €7.2 million from the 2012 agreement.

These payments as well as the milestone payment already received will be entered as income for the current quarter, said BioGaia - adding that the new agreement will have a positive effect on profits during the whole three-year period.

Beyond the short term profit boost, there will also be an eventual income from sales of future products, the firm added.

Related news

Show more

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Custom Biotic Solutions for Digestive Health

Custom Biotic Solutions for Digestive Health

Content provided by ADM: Innovation that Feeds the Future | 10-Oct-2023 | White Paper

A growing body of evidence shows gut health can affect digestive health, well-being, and many health areas in between.

4 reasons children need MFGM, according to science

4 reasons children need MFGM, according to science

Content provided by Valio | 29-Sep-2023 | White Paper

In this white paper, Dr Anu Turpeinen discusses the ample scientific evidence showing why milk fat globule membrane (MFGM) is essential for children’s...

Related suppliers

Follow us


View more